High-yield points
- Disease vs syndrome: idiopathic disease vs association with NF1, Down syndrome, radiation or sickle cell. Syndromes can be aggressive in young children .
- It progresses: 18–59% of unilateral pediatric cases become bilateral, mostly within 3 years, with faster progression in younger children .
- Surgery beats conservative care for symptomatic children (stroke OR 0.33) .
- Indirect vs direct or combined: similar clinical outcomes in children, better angiographic filling with combined, and more wound complications with direct .
- Pial synangiosis: about 4% stroke per hemisphere at 30 days, then durable protection .
- Perioperative: keep children well hydrated and normotensive, avoid crying and hyperventilation, continue aspirin, and watch Hb drops. The youngest children and those with recent TIAs are at highest risk .
- Long-term surveillance: watch for late hemorrhage, especially after cranial radiation .
Landmark papers
- Pial synangiosis (Scott et al., J Neurosurg 2004): 143 patients 21 or younger (271 craniotomies). The 30-day stroke rate was 7.7% per patient (4% per hemisphere), and only 4 of 126 children followed beyond 1 year had a late stroke .
- Japan Adult Moyamoya trial (Miyamoto et al., Stroke 2014): in hemorrhagic moyamoya, mostly adults, direct bypass reduced rebleeding (2.7% vs 7.6% per year) .
- ESO guideline (Bersano et al., Eur Stroke J 2023): suggests direct or combined over indirect bypass in children with hemodynamic impairment, and surgery 6–12 weeks after the last cerebrovascular event .
Moyamoya is a progressive narrowing of the terminal internal carotid arteries and their proximal branches, with a fragile network of basal collaterals (the angiographic "puff of smoke").
- Moyamoya disease: the idiopathic form.
- Moyamoya syndrome: the same arteriopathy associated with another condition, such as neurofibromatosis type 1, Down syndrome, cranial irradiation, sickle cell disease or thyroid disease .
Children usually present with ischemia: transient ischemic attacks (TIAs) and strokes. Surgical revascularization is the mainstay of treatment.
Who gets it: disease vs syndrome
- Associated conditions in a large surgical series (143 patients 21 or younger): neurofibromatosis in 16, cranial irradiation in 13 and Down syndrome in 10. 66 had no predisposing condition .
- Neurofibromatosis type 1:
- Median age at diagnosis was 6, and 42% had optic pathway gliomas.
- Stroke or TIA at diagnosis was more common with bilateral disease (62% vs 34%) and under age 4 (61% vs 40%). This suggests an aggressive form in young children, and early screening should be considered .
- Down syndrome:
- 87% presented with stroke, and diagnosis came later (mean 8.4 vs 6.5 years), suggesting delayed recognition.
- 75% had congenital heart disease .
- Cranial irradiation: the risk is higher in younger children, with optic pathway glioma and with higher doses .
- Sickle cell disease: adding revascularization to transfusion and/or hydroxyurea reduced new strokes and TIAs (OR 0.27) .
Natural history
- Disease progresses, especially in young children:
- Unilateral pediatric disease, three series:
- 58.8% progressed to bilateral disease over a mean of about 32 months, and all 6 with a family history progressed .
- In a cohort of 45, 17.8% progressed over about 53 months, mostly within 3 years. Age under 9 was the only independent predictor .
- 30% progressed after a mean of 2.2 years. Contralateral abnormalities, congenital heart disease, cranial irradiation, Asian ancestry and a family history raised the risk, and children under 7 progressed faster .
- Untreated symptomatic children do worse: in a pediatric meta-analysis, surgery was associated with lower odds of ischemic stroke than conservative management (OR 0.33) .
- Hemodynamically mild disease can sometimes be watched: in a perfusion-based strategy, no conservatively treated child had a stroke. They did have more TIAs and asymptomatic progression than surgically treated hemispheres, so close follow-up is essential .
- Asymptomatic disease (adults, for context):
- Annual stroke risk was 1.0% per hemisphere over 5 years, mostly hemorrhagic .
- Disease progressed at 5.9% per patient-year, more in younger patients .
- Hemorrhage (mostly adults): in the Japan Adult Moyamoya trial, direct bypass reduced rebleeding (2.7% vs 7.6% per year) .
Evaluation
- Imaging: MRI and MR angiography, catheter angiography to stage disease and plan surgery, and perfusion studies to assess hemodynamic impairment. Assessing the posterior cerebral artery is advised .
- Look for the cause: NF1, Down syndrome, sickle cell, prior radiation, cardiac anomalies and a family history. Systematic RNF213 p.R4810K screening isn't recommended (insufficient data) .
- Follow unilateral and asymptomatic disease with MRI and MRA at regular intervals .
Treatment
- Medical: long-term aspirin (antiplatelet therapy) for non-hemorrhagic disease, an expert consensus recommendation . Avoid dehydration and hypotension.
- Surgery (revascularization) is indicated for symptomatic disease and hemodynamic impairment:
- Indirect techniques promote new collaterals from scalp and dural vessels: pial synangiosis, encephaloduroarteriosynangiosis (EDAS), and others.
- Pial synangiosis (143 children, 271 craniotomies): 30-day stroke rate was 7.7% per patient (4% per hemisphere). Only 4 of 126 children followed beyond 1 year had a late stroke, and long-term function depended on preoperative status .
- Children under 2: 2 perioperative strokes in 19 patients, and 68% were independent for age long term .
- Direct (STA–MCA bypass) or combined techniques:
- In 1,091 children, stroke, TIA and functional outcomes were similar for direct or combined vs indirect bypass, though combined bypass gave better angiographic revascularization (Matsushima grade A, OR 3.44) .
- In 2,460 children, direct or combined bypass had more wound complications (RR 2.54) and better angiographic revascularization, without differences in stroke recurrence, morbidity or mortality .
- The European guideline suggests direct or combined over indirect in children with hemodynamic impairment, and recommends direct bypass for hemorrhagic adults .
- Timing: the European guideline suggests surgery 6–12 weeks after the last cerebrovascular event .
- Late outcomes after pial synangiosis (460 children): 3.3% had late death or severe morbidity, mostly from hemorrhage, comorbidities or later brain tumors. Children with prior cranial radiation were at higher risk .
Perioperative care (high-risk window)
- Risk factors for perioperative stroke or TIA: younger age and a TIA within 1 month before surgery . A larger drop in hemoglobin (dilutional anemia) was also associated with stroke (OR 3.90) .
- Expert consensus for indirect surgery :
- Preadmit high-risk children and those with sickle cell disease.
- Give isotonic IV fluids for at least 4 hours before and 24 hours after surgery.
- Continue aspirin.
- Keep an arterial line for at least 24 hours and avoid hypotension.
- Do hourly vital signs and neurological checks.
- Treat a new deficit with a fluid bolus first.
- Crying and hyperventilation lower CO₂ and can trigger ischemia. Pain control and calm are part of stroke prevention. This is a standard anesthetic consideration.
Related topics
- Neurofibromatosis: NF1-associated moyamoya syndrome.
- Arterial Ischemic Stroke in Children: acute stroke management and surgery.
- Cerebral Proliferative Angiopathy: another ischemia-driven angiopathy treated with indirect revascularization.
- Hereditary Vasculopathies: other inherited arteriopathies.
- Hemispherectomy in Children: post-stroke hemispheric epilepsy.
- EC–IC Bypass (Direct STA–MCA Revascularization): step-by-step procedure.
- Pial Synangiosis: step-by-step procedure.
References
- Phi JH, Wang KC, Lee JY, et al. Moyamoya syndrome: a window of moyamoya disease. J Korean Neurosurg Soc 2015;57(6):408–414. doi:10.3340/jkns.2015.57.6.408. PMID 26180607. verified
- Scott RM, Smith JL, Robertson RL, et al. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 2004;100(2 Suppl Pediatrics):142–149. doi:10.3171/ped.2004.100.2.0142. PMID 14758941. verified
- Brosius SN, Vossough A, Fisher MJ, et al. Characteristics of moyamoya syndrome in pediatric patients with neurofibromatosis type 1. Pediatr Neurol 2022;134:85–92. doi:10.1016/j.pediatrneurol.2022.05.013. PMID 35849956. verified
- See AP, Ropper AE, Underberg DL, et al. Down syndrome and moyamoya: clinical presentation and surgical management. J Neurosurg Pediatr 2015;16(1):58–63. doi:10.3171/2014.12.PEDS14563. PMID 25837890. verified
- Scala M, Fiaschi P, Cama A, et al. Radiation-induced moyamoya syndrome in children with brain tumors: case series and literature review. World Neurosurg 2020;135:118–129. doi:10.1016/j.wneu.2019.11.155. PMID 31805403. verified
- Aldana PR, Hanel RA, Piatt J, et al. Cerebral revascularization surgery reduces cerebrovascular events in children with sickle cell disease and moyamoya syndrome: results of the stroke in sickle cell revascularization surgery retrospective study. Pediatr Blood Cancer 2023;70(7):e30336. doi:10.1002/pbc.30336. PMID 37057741. verified
- Park EK, Lee YH, Shim KW, et al. Natural history and progression factors of unilateral moyamoya disease in pediatric patients. Childs Nerv Syst 2011;27(8):1281–1287. doi:10.1007/s00381-011-1469-y. PMID 21552998. verified
- Yeon JY, Shin HJ, Kong DS, et al. The prediction of contralateral progression in children and adolescents with unilateral moyamoya disease. Stroke 2011;42(10):2973–2976. doi:10.1161/STROKEAHA.111.622522. PMID 21836096. verified
- Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 2008;24(2):E17. doi:10.3171/FOC/2008/24/2/E17. PMID 18275294. verified
- Shahbandi A, Sattari SA, Azad TD, et al. The management of symptomatic moyamoya disease in pediatric patients: a systematic review and meta-analysis. Neurosurgery 2024;97(1):65–81. doi:10.1227/neu.0000000000003277. PMID 39560368. verified
- Hayashi T, Hara S, Inaji M, et al. Long-term prognosis of 452 moyamoya disease patients with and without revascularization under perfusion-based indications. J Stroke Cerebrovasc Dis 2023;32(11):107389. doi:10.1016/j.jstrokecerebrovasdis.2023.107389. PMID 37778161. verified
- Kuroda S, Yamamoto S, Funaki T, et al. Five-year stroke risk and its predictors in asymptomatic moyamoya disease: Asymptomatic Moyamoya Registry (AMORE). Stroke 2023;54(6):1494–1504. doi:10.1161/STROKEAHA.122.041932. PMID 37216455. verified
- Kuroda S, Yamamoto S, Funaki T, et al. Disease progression, transient ischemic attack, and de novo parenchymal lesions in asymptomatic moyamoya disease: results of a 5-year interim analysis of the AMORE study. J Neurosurg 2025;142(3):658–666. doi:10.3171/2024.6.JNS24736. PMID 40367646. verified
- Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke 2014;45(5):1415–1421. doi:10.1161/STROKEAHA.113.004386. PMID 24668203. verified
- Bersano A, Khan N, Fuentes B, et al. European Stroke Organisation (ESO) guidelines on moyamoya angiopathy endorsed by Vascular European Reference Network (VASCERN). Eur Stroke J 2023;8(1):55–84. doi:10.1177/23969873221144089. PMID 37021176. verified
- Jackson EM, Lin N, Manjila S, et al. Pial synangiosis in patients with moyamoya younger than 2 years of age. J Neurosurg Pediatr 2014;13(4):420–425. doi:10.3171/2014.1.PEDS13251. PMID 24527861. verified
- Lee KS, Zhang JJY, Bhate S, et al. Surgical revascularizations for pediatric moyamoya: a systematic review, meta-analysis, and meta-regression analysis. Childs Nerv Syst 2023;39(5):1225–1243. doi:10.1007/s00381-023-05868-6. PMID 36752913. verified
- Karsten MB, Smith ER, Scott RM. Late morbidity and mortality following revascularization surgery for moyamoya disease in the pediatric population. J Neurosurg Pediatr 2021;28(2):206–211. doi:10.3171/2021.1.PEDS20944. PMID 34116511. verified
- Gardner Yelton SE, Gatti J, Adil M, et al. Risk factors and imaging biomarkers associated with perioperative stroke in pediatric moyamoya arteriopathy. J Child Neurol 2022;37(12-14):963–969. doi:10.1177/08830738221125554. PMID 36128779. verified
- Gatti JR, Ahmad SA, Gardner Yelton S, et al. Relative anemia and perioperative stroke in children with moyamoya. J Stroke Cerebrovasc Dis 2024;33(1):107476. doi:10.1016/j.jstrokecerebrovasdis.2023.107476. PMID 37976795. verified
- Sun LR, Jordan LC, Smith ER, et al. Pediatric moyamoya revascularization perioperative care: a modified Delphi study. Neurocrit Care 2024;40(2):587–602. doi:10.1007/s12028-023-01788-0. PMID 37470933. verified
Verification (2026-11-03): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. Full texts were not reviewed. References 12–14 are adult studies, included for context. Reference 11 mixes adults and children; only its pediatric findings are used for children. The description of indirect and direct techniques, the imaging work-up details beyond reference 15, avoiding dehydration and hypotension, and the effect of crying and hyperventilation on CO₂ are standard teaching given without a citation. The 18–59% range for contralateral progression spans references 7–9, which differ in design and follow-up. The schematics are original figures.